Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

86.78 -0.73 (-0.83%)
Official Closing Price Updated: 7:00 PM EDT, Sep 23, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,038,536
Open 87.40
Bid (Size) 86.56 (1)
Ask (Size) 86.75 (1)
Prev. Close 87.51
Today's Range 86.09 - 88.01
52wk Range 71.50 - 95.72
Shares Outstanding 2,531,374,696
Dividend Yield 3.00%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Week In Review: Sino Biopharma Subsidiary Enters $307 Million Agreement For Rights To NASH Candidate
Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharma, in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from Inventiva in a $307 million deal. Meanwhile, CASI Pharma... 
Via Talk Markets
Costco Down After Earnings as Analysts Fret About Company Facing Higher Costs
(Friday Market Open) The end of the week isn’t bringing much relief for investors. 
Via Benzinga

Performance

YTD
+12.89%
+12.89%
1 Month
-3.87%
-3.87%
3 Month
-8.08%
-8.08%
6 Month
+6.86%
+6.86%
1 Year
+17.89%
+17.89%

More News

Read More
Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings
Via Benzinga
Renewed Recession Fears Weigh After Rate Hike
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Immutep Issues Development Update For Its Lead Cancer Candidate
Via Benzinga
Merck Stock Surges After Winning Patent Battle Vs. Viatris Over Two Key Drugs
Via Investor's Business Daily
Looking At Merck & Co's Recent Whale Trades
Via Benzinga
Merck Animal Health to Acquire Vence
From Merck & Co., Inc.
Via Business Wire
Nanobiotix Establishes Recommended Dose For Registrational Study Of Head & Neck Combo Therapy Trial
Via Benzinga
LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer
From Merck & Co., Inc.
Via Business Wire
U.S. District Court Rules In Favor of Merck in Sitagliptin Phosphate Patent Lawsuit
From Merck & Co., Inc. Merck
Via Business Wire
Why Is Evaxion Biotech (EVAX) Stock Up Today?
Via InvestorPlace
3 Stocks That Could Rocket on Biden’s Cancer Moonshot
Via InvestorPlace
Merck To Start New Islatravir HIV Trials With Lower Dose After FDA Hold
Via Benzinga
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection
From Merck & Co., Inc.
Via Business Wire
Stocks Secure Wins In Last Hour Of Trading
Via Talk Markets
Take-Two Gets Beat Down After Leak of Its Popular Grand Theft Auto VI
Via Benzinga
7 Penny Stocks That Actually Have a Buy Rating
Via InvestorPlace
Why Hedge Funds Are Piling In These 2 High Yielding Stocks
Via Benzinga
7 Undervalued Stock Picks to Beat the September Market Slump
Via InvestorPlace
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children
From Merck & Co., Inc.
Via Business Wire
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
Via Investor's Business Daily
What Are Whales Doing With Merck & Co
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.